Accession Number: | 0001209191-21-057037 |
Date: | 2021-09-20 |
Issuer: | AVITA MEDICAL, INC. (RCEL) |
Original Submission Date: |
CROWE SUZANNE
C/O AVITA THERAPEUTICS, INC.
28159 AVENUE STANFORD, SUITE 220
VALENCIA, CA 91355
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-09-20 | P | 1,066 | a | $17.08 | 4,112 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | reflects 5,330 of the issuer's chess depositary interests ("cdis"). cdis are units of beneficial ownership in shares of common stock of the issuer that are publicly traded on the australian securities exchange (the "asx") and held by chess depositary nominees pty, limited, a subsidiary of asx limited, the company that operates the asx. five cdis are equivalent to one share of the issuer's common stock and have all the rights and privileges of common stock. |
f2 | the purchase price was converted from a$4.72, using the exchange rate as in effect on the date of the transaction, and reflects the 5:1 consolidation ratio applied in converting cdis to shares of the issuer's common stock. |
f3 | the reporting person holds 20,560 cdis, which translate into the 4,112 shares of common stock set forth above. |